Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...

Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

Amgen and AstraZeneca have announced full results from the Phase III, registrational WAYPOINT trial showing that Tezspire ...

Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...

(RTTNews) - The Phase III WAYPOINT trial results revealed that AstraZeneca (AZN.L, AZN) and Amgen's (AMGN) TEZSPIRE (tezepelumab-ekko) significantly decreased nasal polyp severity, reduced the ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Amgen (AMGN) and AstraZeneca (AZN) announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also ...

Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery ...